Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $7.33.

Separately, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th.

Amylyx Pharmaceuticals Price Performance

Amylyx Pharmaceuticals stock opened at $3.66 on Monday. The company has a market cap of $324.28 million, a price-to-earnings ratio of -0.96 and a beta of -0.51. Amylyx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $7.27. The stock’s 50-day moving average is $3.55 and its 200-day moving average is $4.04.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The company had revenue of ($0.67) million for the quarter. Research analysts anticipate that Amylyx Pharmaceuticals will post -2.2 EPS for the current year.

Insider Transactions at Amylyx Pharmaceuticals

In related news, CEO Justin B. Klee sold 7,471 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $4.04, for a total value of $30,182.84. Following the completion of the transaction, the chief executive officer now owns 3,176,788 shares of the company’s stock, valued at approximately $12,834,223.52. This represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Bernhardt G. Zeiher acquired 10,000 shares of the stock in a transaction on Thursday, March 20th. The shares were acquired at an average price of $3.70 per share, with a total value of $37,000.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $37,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 27,169 shares of company stock valued at $97,274. Corporate insiders own 11.70% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AMLX. FMR LLC grew its holdings in Amylyx Pharmaceuticals by 292.0% during the 3rd quarter. FMR LLC now owns 221,001 shares of the company’s stock worth $716,000 after acquiring an additional 164,622 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Amylyx Pharmaceuticals by 144.4% in the third quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock worth $455,000 after purchasing an additional 83,048 shares in the last quarter. Barclays PLC increased its holdings in Amylyx Pharmaceuticals by 91.1% in the third quarter. Barclays PLC now owns 84,572 shares of the company’s stock valued at $274,000 after buying an additional 40,319 shares during the last quarter. Walleye Capital LLC raised its stake in Amylyx Pharmaceuticals by 986.5% during the third quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock valued at $2,173,000 after buying an additional 608,874 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Amylyx Pharmaceuticals by 17.5% during the 3rd quarter. Geode Capital Management LLC now owns 551,039 shares of the company’s stock worth $1,786,000 after buying an additional 82,173 shares during the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.